CEFOTAXIME- cefotaxime injection, powder, for solution United States - English - NLM (National Library of Medicine)

cefotaxime- cefotaxime injection, powder, for solution

lupin pharmaceuticals, inc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 500 mg - cefotaxime for injection usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. - lower respiratory tract infections , including pneumonia, caused bystreptococcus pneumoniae (formerlydiplococcus pneumoniae ),streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g.,enterococcus faecalis ),staphylococcus aureus (penicillinase and non-penicillinase producing),escherichia coli ,klebsiella species,haemophilus influenzae (including ampicillin resistant strains),haemophilus parainfluenzae ,proteus mirabilis ,serratia marcescens *,enterobacter species, indole positiveproteus andpseudomonas species (includingp. aeruginosa ). - genitourinary infections . urinary tract infections caused byenterococcus species,staphylococcus epidermidis ,staphylococcus aureus *, (penicillinase and non-penicillinase producing),citrobacter species,enterobacter species,escherichia coli ,kl

CEFOTAXIME injection, powder, for solution United States - English - NLM (National Library of Medicine)

cefotaxime injection, powder, for solution

hikma pharmaceuticals usa inc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 1 g - cefotaxime for injection, usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes* (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species, haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae , proteus mirabilis , serratia marcescens* , enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). (2) genitourinary infections . urinary tract infections caused by enterococcus species, staphylococcus epidermidis , staphylococcus aureus* , (penicillinase and non-penicillinase producing), citrobacter species, enterobac

CEFOTAXIME injection United States - English - NLM (National Library of Medicine)

cefotaxime injection

west-ward pharmaceuticals corp - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 10 g - cefotaxime for injection, usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes* (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species, haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae , proteus mirabilis , serratia marcescens* , enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). (2) genitourinary infections . urinary tract infections caused by enterococcus species, staphylococcus epidermidis , staphylococcus aureus* , (penicillinase and non-penicillinase producing), citrobacter species, enterobac

Cefotaxime (AFT) New Zealand - English - Medsafe (Medicines Safety Authority)

cefotaxime (aft)

aft pharmaceuticals ltd - cefotaxime sodium 1048.1mg equivalent 1 g cefotaxime (+ 5% overage) - powder for injection - 1 g - active: cefotaxime sodium 1048.1mg equivalent 1 g cefotaxime (+ 5% overage) - cefotaxime is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. · septicaemia. · respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. · urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. · soft tissue infections: cellulitis, peritonitis and wound infections. · bone and joint infections: osteomyelitis, septic arthritis. · obstetric and gynaecological infections: pelvic inflammatory disease. · gonorrhoea: particularly if penicillin-resistant. · other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of cefotaxime prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. cefotaxime should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

Cefotaxime (AFT) New Zealand - English - Medsafe (Medicines Safety Authority)

cefotaxime (aft)

aft pharmaceuticals ltd - cefotaxime sodium 2096.2mg equivalent 2 g cefotaxime (+ 5% overage) - powder for injection - 2 g - active: cefotaxime sodium 2096.2mg equivalent 2 g cefotaxime (+ 5% overage) - cefotaxime is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. · septicaemia. · respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. · urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. · soft tissue infections: cellulitis, peritonitis and wound infections. · bone and joint infections: osteomyelitis, septic arthritis. · obstetric and gynaecological infections: pelvic inflammatory disease. · gonorrhoea: particularly if penicillin-resistant. · other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. the administration of cefotaxime prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. cefotaxime should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.

CEFOTAXIME injection, powder, for solution United States - English - NLM (National Library of Medicine)

cefotaxime injection, powder, for solution

wockhardt usa llc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 500 mg - treatment cefotaxime for injection, usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species, haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae , proteus mirabilis , serratia marcescens *, enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). (2) genitourinary infections . urinary tract infections caused by enterococcus species, staphylococcus epidermidis , staphylococcus aureus *, (penicillinase and non-penicillinase producing), citrobacter species,

CEFOTAXIME SANDOZ cefotaxime 2g powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cefotaxime sandoz cefotaxime 2g powder for injection vial

sandoz pty ltd - cefotaxime sodium, quantity: 2096.4 mg (equivalent: cefotaxime, qty 2000 mg) - injection, powder for - excipient ingredients: - indications: cefotaxime is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower); infections of the urinary tract; septicaemia (concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism); intra-abdominal infection; gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoea); ear, nose and throat infections; skin and skin structure infections; bone and joint infections; meningitis: cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or benzylpenicillin) for initial therapy in children (excluding neonates) pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime may be used for the prevention of post-operative infec

Cefotaxime (Pacific) New Zealand - English - Medsafe (Medicines Safety Authority)

cefotaxime (pacific)

viatris limited - cefotaxime sodium 1048mg equivalent to 1 g cefotaxime - powder for injection - 1 g - active: cefotaxime sodium 1048mg equivalent to 1 g cefotaxime excipient: nitrogen

Cefotaxime (Pacific) New Zealand - English - Medsafe (Medicines Safety Authority)

cefotaxime (pacific)

viatris limited - cefotaxime sodium 2097mg equivalent to 2 g cefotaxime - powder for injection - 2 g - active: cefotaxime sodium 2097mg equivalent to 2 g cefotaxime excipient: nitrogen

Cefotaxime (Pacific) New Zealand - English - Medsafe (Medicines Safety Authority)

cefotaxime (pacific)

viatris limited - cefotaxime sodium 524mg equivalent to 500 mg cefotaxime - powder for injection - 500 mg - active: cefotaxime sodium 524mg equivalent to 500 mg cefotaxime